Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AbCellera Biologics Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $8.955M Beat $5.909M Estimate

Author: Benzinga Newsdesk | November 06, 2025 04:09pm
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 12.43 percent. This is a 11.76 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $8.955 million which beat the analyst consensus estimate of $5.909 million by 51.55 percent. This is a 37.62 percent increase over sales of $6.507 million the same period last year.

Posted In: ABCL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist